This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Walgreens Boots (WBA) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Walgreens Boots' (WBA) health and wellness sales increase for fiscal Q4 on growing demand for at-home COVID-19 tests and vitamins.
Should Vanguard S&P SmallCap 600 Growth ETF (VIOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOG
Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPSM
Quidel Corporation (QDEL) Reports Solid Preliminary Q3 Revenues
by Zacks Equity Research
Quidel's (QDEL) revenue growth in the third quarter is likely to have been boosted by robust sales of its SARS-related products.
Catalent (CTLT) Expands Presence in Japan Via New Facility
by Zacks Equity Research
Catalent's (CTLT) new site is expected to become a key hub in its Asia-Pacific Clinical Supply Services network by significantly boosting its business.
Zacks Industry Outlook Highlights: 10x Genomics, Omnicell, Inspire Medical Systems and Cerner
by Zacks Equity Research
Zacks Industry Outlook Highlights: 10x Genomics, Omnicell, Inspire Medical Systems and Cerner
Here's Why You Should Add DexCom (DXCM) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its slew of favorable coverage decisions for its G6 CGM System.
Buy 3 Medical Info Systems Stocks to Brave Industry-wide Challenges
by Urmimala Biswas
Stocks like 10x Genomics Inc. (TXG), Omnicell, Inc. (OMCL) and Inspire Medical Systems, Inc. (INSP) are expected to gain despite pandemic-led disruptions.
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.
Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Omnicell (OMCL) Soars 3.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Omnicell (OMCL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) broad array of services.
Surmodics' (SRDX) Latest Sublime Catheter Expands Patient Pool
by Zacks Equity Research
Surmodics' (SRDX) latest addition is expected to aid in performing more complex interventions which were earlier not possible.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Dexcom's (DXCM) G6 CGM System Gets Coverage in Manitoba
by Zacks Equity Research
Dexcom's (DXCM) CGM System is expected to simplify diabetes management due to increasing access to the life changing technology.
Reasons to Hold on to Inari Medical (NARI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Inari Medical (NARI) owing to its focus on understanding the venous system and its commitment toward patient care.
3 Sectors Looking Up Ahead of Q3 Earnings Despite COVID-19 Woes
by Urmimala Biswas
There has been notable job gains in automotive, hospitality, retail, social assistance and in professional and business services through the past few months.
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs as well as in domestic revenues in fiscal 2022 Q1.
Here's Why You Should Retain Syneos Health (SYNH) For Now
by Zacks Equity Research
Investors are optimistic about Syneos Health (SYNH), given the strength in its Clinical Solutions business and notable partnership deals.
3 Reasons Growth Investors Will Love Omnicell (OMCL)
by Zacks Equity Research
Omnicell (OMCL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
CPSI vs. OMCL: Which Stock Is the Better Value Option?
by Zacks Equity Research
CPSI vs. OMCL: Which Stock Is the Better Value Option?
Here's Why You Should Add Omnicell (OMCL) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Omnicell (OMCL) on its strategic acquisitions and partnerships supporting each of the three legs of its strategy.
Syneos Health's (SYNH) New Buyout Boosts Clinical Solutions Arm
by Zacks Equity Research
Syneos Health (SYNH) acquisition of StudyKIK strengthens the former's ability to provide technology and insight-driven solutions.
Omnicell (OMCL) New Buyout Expands Patient Engagement Suite
by Zacks Equity Research
With the FDS Amplicare acquisition, Omnicell (OMCL) is expected to gain from several healthcare trends, banking on its offerings of digital technologies, SaaS solutions, and tech-enabled services.
Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPSM